Status:
UNKNOWN
Improving Glycaemic Control With L-carnitine
Lead Sponsor:
University of Nottingham
Conditions:
Type 2 Diabetes
Eligibility:
MALE
18-60 years
Phase:
PHASE2
Brief Summary
A characteristic of Type 2 diabetes is a high blood glucose level, which is partly caused by the inability of insulin to stimulate glucose uptake into our muscles (insulin resistance). Insulin resista...
Eligibility Criteria
Inclusion
- Body mass index (BMI) 27-37 kg/m2
- Male
- Age 18-60 years old
- Type 2 diabetes mellitus reasonably well controlled (HbA1c less than or equal to 58 mmol/mol) on diet therapy or metformin alone
- Not taking anti-diabetes medication other than metformin
- Understand verbal and/or written explanation of the study requirements
Exclusion
- Malignancy (excluding localised basal and squamous cell skin cancer)
- Metabolic diseases (stable treated hypothyroidism allowed)
- Active cardiovascular disease (current angina, myocardial infarct, or coronary artery surgery/angioplasty within 12 months)
- Primary muscle disorders
- Cerebrovascular disease
- Neurological disease e.g. epilepsy, Parkinsons disease
- Active respiratory disease
- Active gastrointestinal or liver disease
- Renal impairment (eGFR \<60 ml/min)
- Clotting dysfunction
- Anti-diabetes medication other than metformin
- Other medications that may affect glucose tolerance (e.g. corticosteroids), muscle metabolism, or safety (e.g. anticoagulants)
- Any other conditions in addition to the above that the investigators consider may affect study measurements or safety
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02197299
Start Date
August 1 2014
Last Update
December 3 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
David Greenfield Human Physiology Unit, School of Life Sciences, The University of Nottingham
Nottingham, United Kingdom, NG72UH